Physician profile

Krishna P Bhat

Physical Medicine & Rehabilitation · Sanford, NC

NPI 1891746012

$30,179.80

in general payments reported to CMS, 2019-2025

44 companies · $3,006 in 2025

The $3,006 reported for 2025 was more than what 96% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$8,020.68
Travel and Lodging$707.39
Education$21.00

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbott Laboratories $22,360.06 2019-2025 Proclaim, Eterna, Octrode
Saluda Medical Americas, INC. $1,279.94 2023-2025 Evoke, Evoke Scs
Collegium Pharmaceutical, INC. $1,219.80 2019-2025 Belbuca, Xtampza
Boston Scientific Corporation $1,016.23 2019-2023
Abbvie INC. $634.04 2021-2025 Ubrelvy, Qulipta, Botox
Si-Bone, INC. $545.22 2020-2025
Nevro Corp. $456.04 2019-2021
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $334.97 2019-2025 Relistor
Amgen INC. $248.86 2019-2022
Scilex Pharmaceuticals INC. $242.61 2019-2024
Assertio Therapeutics, INC. $173.40 2019-2020
Spineart USA INC $159.53 2021
Sonex Health, INC. $133.67 2022
Virtus Pharmaceuticals LLC $124.95 2023-2025 Levorphanol Tartrate
Novo Nordisk INC $120.13 2019-2023 Wegovy
Show all 44 companies
CompanyGeneral paymentsYearsTop products
Pfizer INC. $104.91 2019-2023
Biodelivery Sciences International, INC. $84.49 2019-2021
Fidia Pharma USA INC. $80.45 2019-2024 Hymovis, Triluron, Hyalgan
Arbor Pharmaceuticals, INC. $77.30 2019-2022
Ibsa Pharma INC. $71.41 2021-2022
Almatica Pharma LLC $62.26 2021
Vertos Medical, INC. $57.70 2021
Allergan, INC. $56.42 2021-2022
Merz Pharmaceuticals, LLC $49.67 2024-2025 Xeomin
Vertex Pharmaceuticals Incorporated $46.82 2025
Valinor Pharma, LLC $43.34 2024-2025 Movantik
Sentynl Therapeutics, INC. $41.07 2019
Depuy Synthes Sales INC. $33.30 2020
Lilly USA, LLC $29.00 2025 Mounjaro, Zepbound
Averitas Pharma INC. $28.45 2023 Qutenza
Mdd US Operations, LLC $26.43 2019
Forte Bio-Pharma LLC $25.17 2025 Prolate, Nalocet, Tanlor
Biotronik Nro, INC. $24.96 2025 Prospera
Lundbeck LLC $24.85 2022
Bioventus LLC $24.29 2022
Hikma Pharmaceuticals USA $21.00 2024 Kloxxado
Novartis Pharmaceuticals Corporation $19.41 2020
Azurity Pharmaceuticals, INC. $17.29 2024 Horizant
Nalu Medical, INC. $16.41 2021
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $15.50 2023 Lifevest
Medtronic, INC. $13.45 2021
Astrazeneca Pharmaceuticals LP $12.02 2019
Kaleo, INC. $11.55 2019
Teva Pharmaceuticals USA, INC. $11.43 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Krishna P Bhat

$30,179.80

in general payments reported 2019-2025

Years
2019-2025
Top company
Abbott Laboratories
Context
The $3,006 reported for 2025 was more than what 96% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).

https://glasscript.com/doctor/616233/krishna-p-bhat

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.